Neuralink is now using Neko Health's full-body scan data to decide who gets a brain chip, and almost nobody is talking about it.
According to a new report, Neuralink and Neko Health, the body-scanning startup backed by Spotify co-founder Daniel Ek, are collaborating to screen candidates for Neuralink's clinical trials. The method: feed Neko's deep diagnostic body-scan data into the candidate selection process, filtering humans for brain-computer interface implants with a level of biological precision that has never existed before.
This is not a small R&D side project. This is the infrastructure layer for human augmentation trials, and it is being built right now.
Why This Is Bigger Than It Looks
Clinical trial screening has always been the bottleneck. Slow, expensive, and wildly inconsistent, the traditional process eliminates viable candidates and lets bad matches through. By layering Neko's whole-body imaging and biomarker data into the selection funnel, Neuralink could dramatically compress the timeline between prototype and human deployment.
Faster trials mean faster regulatory submissions. Faster regulatory submissions mean faster approvals. If this model works, it does not stay inside Neuralink. Every biotech company running implant or gene therapy trials will want this pipeline.
The Ethical Minefield Nobody Is Pricing In
Here is where it gets uncomfortable. Who controls the scan data? Who decides which biomarkers qualify someone for a brain implant and which ones exclude them? Neko is a private company. Neuralink is a private company. There is no public audit trail for how these decisions get made.
The collaboration could accelerate medical advancement in ways that genuinely help people with paralysis, neurological disorders, and severe cognitive impairments. That is the optimistic read. The pessimistic read is that two well-capitalized private entities are now jointly gatekeeping access to the most invasive consumer technology ever built, using health data that most people assumed was only for their own wellness tracking.
Regulators in the US and EU are already behind on brain-computer interface oversight. This collaboration widens that gap further.
What Crypto and Tech Investors Should Watch
The convergence of health data infrastructure, AI screening, and human augmentation trials is creating an entirely new asset category. Companies building the data layers beneath these trials, think health data oracles, decentralized identity verification, and privacy-preserving computation, are sitting on a use case that just became dramatically more urgent.
Watch for regulatory statements from the FDA and EU medical device bodies in the coming months. Any move toward mandatory data transparency frameworks for trial screening could reshape which infrastructure players win this race.
The body scan is no longer just a wellness tool. It is now a key to experimental technology. Act accordingly.